Women with polycystic ovary syndrome are roughly four times more likely to develop fatty liver disease than women without it, even after accounting for weight, diabetes, and other shared risk factors. That statistic alone would justify paying attention, but the connection runs deeper than shared metabolic ground. The hormonal hallmarks of PCOS, particularly excess androgens, appear to drive liver fat accumulation through pathways that operate independently of body weight, which means lean women with PCOS are not off the hook.
How Strong Is the Association
The numbers are striking and consistent across study designs. A large hospital-based analysis in the United States found that women with PCOS had almost eight times the unadjusted odds of also having fatty liver disease. After adjusting for age, race, obesity, high blood pressure, abnormal cholesterol, diabetes, and thyroid problems, the odds remained more than four times higher in the PCOS group.1PubMed Central. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome A meta-analysis pooling data from multiple studies reached a similar conclusion, reporting nearly four-fold higher odds of fatty liver in women with PCOS compared with healthy controls.2PubMed Central. Are Women With Polycystic Ovarian Syndrome at a High Risk of Non-Alcoholic Fatty Liver Disease; A Meta-Analysis
Prevalence figures vary depending on which diagnostic tool is used. One study comparing women with PCOS to controls found fatty liver rates of about 10 to 32 percent in the PCOS group (depending on the screening index) versus roughly 1 to 4 percent in controls.3Scientific Reports. Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome Broader estimates from review literature place the range at 30 to 50 percent in women with PCOS, which is substantially higher than the general female population. The gap is wide enough that the question is no longer whether these two conditions travel together but why, and what to do about it.
Why PCOS Pushes Fat Into the Liver
Insulin resistance is the most obvious shared ingredient. Most women with PCOS have some degree of impaired insulin signaling, and insulin resistance is also the central metabolic driver of fatty liver disease. When cells respond poorly to insulin, the body compensates by producing more of it. Elevated insulin promotes fat storage in the liver and makes it harder for the liver to export that fat. Waist circumference, insulin resistance, low HDL cholesterol, and a PCOS diagnosis all independently predicted the presence of liver fat in one clinical study.4PubMed Central. Prevalence of hepatic steatosis in women with polycystic ovary syndrome
But insulin resistance alone does not explain the full picture. Excess androgens, the hormonal signature of PCOS, appear to have a direct and sex-specific effect on liver cells. Laboratory work on human liver cells has shown that testosterone ramps up the genes responsible for making new fat and boosts fat production in cells from female donors but not male donors.5PubMed Central. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database Animal studies have confirmed this by showing that elevated testosterone shuts down a key energy-sensing pathway in the liver, directly causing fat buildup.6PubMed. Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome
The relationship between androgen levels and liver fat is not perfectly linear, though. One analysis of women found that liver fat content increased alongside rising androgen levels up to a certain threshold. Beyond that threshold, higher androgen levels were actually associated with less liver fat, suggesting the relationship follows a curve rather than a straight line.7PubMed. Role of Androgen in Liver Fat Content in Women: Metabolically Advantageous or Disadvantageous? This helps explain why not every woman with high testosterone develops fatty liver and why some PCOS phenotypes carry more liver risk than others.
Two additional mechanisms deserve attention. First, fat tissue itself does not function normally in PCOS. Research has documented impaired fat storage capacity, disrupted signaling molecules released by fat cells (including lower adiponectin, which normally protects the liver), increased inflammation, and mitochondrial stress in the fat tissue of women with PCOS.8PubMed Central. Adipose Tissue Dysfunction in Polycystic Ovary Syndrome When fat tissue cannot do its job properly, excess fatty acids get diverted to the liver instead. Second, changes in the gut microbiome associated with PCOS appear to increase intestinal permeability and chronic low-grade inflammation, which in turn promotes fat accumulation and oxidative damage in the liver.9PubMed. Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics
The Risk Does Not Stop at Fat Buildup
Fatty liver is a spectrum. Simple fat accumulation in the liver is the earliest stage. A subset of people progress to a more aggressive form involving active liver cell injury and inflammation, commonly called NASH (or, under newer naming conventions, metabolic-associated steatohepatitis). From there, repeated cycles of injury and repair can produce scar tissue, eventually leading to advanced fibrosis or cirrhosis. Women with PCOS appear to be at increased risk not just for developing initial fat buildup but for progressing to these more dangerous stages.
A study of over 100 women with confirmed fatty liver disease found that those who also had PCOS were significantly more likely to have severe liver cell ballooning, a hallmark of NASH, and advanced fibrosis. Even after adjusting for age and body weight, PCOS remained independently linked to roughly a three-fold increase in severe ballooning and a seven-fold increase in advanced scarring.10PubMed Central. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis Perhaps most alarming, women with PCOS who had advanced fibrosis were on average five years younger than those without PCOS who had the same degree of scarring.10PubMed Central. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis
Because PCOS develops during the reproductive years, women may accumulate decades of liver damage if the condition goes unmanaged. A review in the World Journal of Gastroenterology made this point directly: given how young women with PCOS may be when fatty liver first develops, they face a prolonged window of exposure during which simple steatosis can quietly advance to serious liver disease.11PubMed Central. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome A separate study examining fibrosis markers in young women with PCOS found that higher androgen levels were independently associated with worsening fibrosis scores, especially in non-obese patients. In obese patients, insulin resistance was the stronger predictor.12PLoS ONE. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS
Lean Women With PCOS Still Develop Fatty Liver
One of the most counterintuitive findings in this area is that you do not need to be overweight for PCOS to affect your liver. A study of lean women (those with a normal body mass index) found fatty liver in about 28 percent of the PCOS group compared with roughly 9 percent of controls.13PubMed Central. Predictivity of fatty liver index for non-alcoholic fatty liver disease in lean females with polycystic ovary syndrome A review pulling together multiple studies reported even more dramatic numbers in some populations: lean women with PCOS had up to a 14-fold higher presence of fatty liver compared with lean women without it, while the gap narrowed considerably in obese women.14The Journal of Clinical Endocrinology & Metabolism. Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome – Section: Body Mass Index A UK longitudinal study found that the risk of developing fatty liver was nearly double for lean women with PCOS compared to weight-matched women without PCOS.14The Journal of Clinical Endocrinology & Metabolism. Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome – Section: Body Mass Index
This is exactly where the androgen pathway and fat tissue dysfunction become important. If the connection were purely about excess body weight, lean women should be protected. They are not, because the hormonal and metabolic disturbances of PCOS affect liver fat metabolism regardless of how much a person weighs. Clinicians who screen for liver problems only in overweight patients with PCOS will miss a meaningful fraction of affected women.
Adolescents Are Not Too Young
Fatty liver disease associated with PCOS is not limited to adult women. Research has documented the combination in teenagers. A case-control study comparing adolescent girls with PCOS to controls found liver fat on ultrasound in about 23 percent of the PCOS group versus 6 percent of controls. When using scoring indices, the gap was wider still, with up to 41 percent of PCOS adolescents flagged versus 14 percent of controls.15PubMed Central. The Burden of Non-Alcoholic Fatty Liver Disease in Adolescents with Polycystic Ovary Syndrome: A Case–Control Study Across the literature, the estimated incidence of fatty liver in girls with PCOS ranges from roughly 7 to 60 percent depending on the study population and diagnostic method, consistently two and a half to four times higher than in girls without PCOS.16Medical Science Monitor. Unraveling the Interplay between Nonalcoholic Fatty Liver Disease and Polycystic Ovary Syndrome in Adolescents: Pathogenesis, Prevalence, and Management Strategies
Older studies have found elevated liver enzymes in roughly 15 percent of obese adolescent girls with PCOS, and imaging-based studies have detected liver fat in nearly half of adolescent PCOS patients who were also obese.17The Journal of Clinical Endocrinology & Metabolism. Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome – Section: Age The concern here is duration of exposure. A teenager who develops fatty liver at 15 and goes undiagnosed until her 40s has spent 25 years quietly accumulating potential damage. Early identification matters more in this group than almost any other.
Screening and Detection Without Liver Biopsy
Liver biopsy remains the gold standard for diagnosing and staging fatty liver disease, but it is invasive and impractical for routine screening. Several non-invasive indices have been tested in women with PCOS. A recent study found that the hepatic steatosis index and the fatty liver index both performed well for identifying fatty liver in this population, with diagnostic accuracy around 88 to 89 percent.18PubMed. The role of hepatic steatosis Index, fatty liver Index, and metabolic and hormonal biomarkers in differentiating MASLD in polycystic ovary syndrome These indices use combinations of routine lab results (liver enzymes, blood sugar measures, lipid levels) and basic measurements (waist circumference, BMI) that are already collected during standard PCOS workups.
For detecting fibrosis, the picture is a bit more mixed. One study found that certain fibrosis scoring systems (like the FIB-4 score) flagged higher risk in women with PCOS than controls, while other scoring systems did not show a difference.19PubMed. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis Women with PCOS who also had metabolic syndrome scored dramatically higher on both steatosis and fibrosis indices than those without metabolic syndrome.19PubMed. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis Some clinical practice guidelines have recommended screening women with PCOS for fatty liver disease when insulin resistance or metabolic syndrome is present, and have suggested specialist referral for those who screen positive.20The Journal of Clinical Endocrinology & Metabolism. Clinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Study
In practice, many women with PCOS are never screened for liver problems. If you have PCOS and your doctor has never checked your liver enzymes or discussed fatty liver with you, it is worth raising the subject, particularly if you have irregular periods combined with signs of insulin resistance such as skin tags, darkened skin patches around the neck, or difficulty managing weight.
Lifestyle Approaches That Address Both Conditions
Diet, exercise, and weight management are the first-line approach for both PCOS and fatty liver disease, and for good reason: they target the insulin resistance that fuels both conditions. Even modest weight loss, typically in the range of 5 to 10 percent of body weight, can significantly reduce liver fat.21PubMed Central. Nonalcoholic fatty liver disease and polycystic ovary syndrome
A small randomized trial tested a ketogenic diet in obese women with PCOS and liver dysfunction. After 12 weeks, signs of fatty liver disappeared in six of seven participants on the ketogenic diet, compared with just one of ten in the control group.22PubMed. Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: A randomized, open-label, parallel-group, controlled pilot trial This was a very small pilot study, so the results should be interpreted cautiously, but they illustrate how powerfully dietary changes can shift liver fat in this population. The ketogenic approach is not for everyone, and sustainability matters more than any particular dietary label. What the evidence broadly supports is reducing refined carbohydrates and processed foods, both of which spike insulin, while emphasizing whole foods, fiber, and healthy fats.
Exercise contributes independently of weight loss. Aerobic activity and resistance training both improve insulin sensitivity, and the combination tends to work better than either alone. For women with PCOS, consistent physical activity also helps lower androgen levels, which may provide additional liver protection beyond the metabolic benefits.
Medications That Target the Overlap
Metformin has been used for decades to manage insulin resistance in PCOS, and there is growing evidence that it benefits the liver as well. One study showed that metformin significantly improved hepatic steatosis index scores in non-obese women with PCOS, suggesting a reduction in liver fat, though this improvement was not seen in obese subgroups.23PubMed Central. Metformin Improves the Hepatic Steatosis Index in Non-Obese Patients with Polycystic Ovary Syndrome Animal research has provided a possible explanation: metformin appears to reduce liver fat accumulation in PCOS by rescuing mitochondrial function and restoring cellular cleanup processes in the liver.24PubMed Central. Metformin Alleviates Liver Metabolic Dysfunction in Polycystic Ovary Syndrome by Activating the Ethe1/Keap1/PINK1 Pathway
GLP-1 receptor agonists, the drug class that includes liraglutide and semaglutide, are generating significant interest for their ability to address multiple aspects of PCOS simultaneously. They promote weight loss, improve insulin sensitivity, and reduce appetite.25PubMed Central. Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies In one trial of obese women with PCOS and fatty liver, liraglutide treatment significantly reduced a blood marker of liver fibrosis (a protein associated with collagen turnover) in the PCOS group, though the same improvement was not statistically significant in the control group without PCOS.26PubMed. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease This raises the possibility that GLP-1 drugs may be especially useful in women who carry both diagnoses, though larger trials are still needed.
Vitamin E has also been recommended by some clinical practice guidelines for women with PCOS-related fatty liver, particularly those with insulin resistance and metabolic syndrome, with the guidance to involve a specialist team.20The Journal of Clinical Endocrinology & Metabolism. Clinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Study Vitamin E acts as an antioxidant in the liver and has shown benefit in broader NASH populations, though long-term safety at high doses is debated.
Inositol and Other Supplements
Inositol, particularly myo-inositol and D-chiro-inositol, has become a popular supplement among women with PCOS because of its effects on insulin signaling and ovarian function. Its potential benefits for the liver are less well established but worth noting. A systematic review found that inositol supplementation in animal models of fatty liver reduced liver triglycerides and cholesterol accumulation and preserved normal liver structure. In one included human trial, a related compound called pinitol significantly reduced liver fat, post-meal triglycerides, and a marker of liver damage while boosting antioxidant enzyme activity.27PubMed Central. Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation The evidence base remains thin, and larger human trials are needed before drawing strong conclusions, but the overlap between inositol’s mechanism of action and the metabolic dysfunction seen in PCOS-associated fatty liver makes it a plausible area for future research.
Genetic Factors That Modify Individual Risk
Not every woman with PCOS will develop fatty liver, and genetics partially explain why. A study examining two European cohorts of women with PCOS found that carriers of a particular variant in the PNPLA3 gene had significantly increased liver stiffness, a surrogate for fibrosis.28PubMed. Liver phenotypes in PCOS: Analysis of exogenous and inherited risk factors for liver injury in two European cohorts The PNPLA3 gene variant is already well known in liver research as one of the strongest genetic risk factors for fatty liver disease in the general population. In women with PCOS, it may compound the hormonal and metabolic hits that already predispose the liver to fat accumulation and scarring.
This kind of genetic layering has practical implications. A woman with PCOS who also carries liver-risk gene variants may develop more severe disease at a younger age and with less metabolic provocation than someone without those variants. As genetic testing becomes more accessible, it could eventually help clinicians identify which women with PCOS need the most aggressive liver monitoring, though routine genetic screening for this purpose is not yet standard practice.
Pregnancy and the Double Burden
Women with PCOS already face higher rates of gestational diabetes, preeclampsia, and other pregnancy complications. Adding fatty liver to the mix creates additional metabolic strain. Women who have both PCOS and fatty liver tend to exhibit a more adverse metabolic profile overall, including worse insulin resistance, more visceral fat, and more abnormal lipid levels than those with PCOS alone.29PubMed Central. Reproductive Health and Nonalcoholic Fatty Liver Disease in Women: Considerations Across the Reproductive Lifespan The exact impact of having both conditions simultaneously during pregnancy is still an evolving area of investigation, but the metabolic burden is clearly compounded.
For women planning pregnancy, this argues for addressing liver health before conception if possible. Improving insulin sensitivity, reducing liver fat through diet and exercise, and working with a care team that is aware of both the PCOS and the liver component can help optimize the metabolic environment for a healthier pregnancy. Medications like metformin are sometimes continued into early pregnancy for women with PCOS, and their liver-related benefits during this window are an area of active clinical interest.
Menopause Adds Another Layer
Fatty liver disease becomes more common in women after menopause, likely driven by the loss of estrogen’s protective effects on metabolic health. A review of the available evidence found that a large proportion of the global adult female population, up to about 30 percent, is affected by fatty liver, and several studies point to higher rates among postmenopausal women, though not all studies agree on the strength of that association.30PubMed Central. The Effect of Menopausal Status, Insulin Resistance and Body Mass Index on the Prevalence of Non-Alcoholic Fatty Liver Disease For women with PCOS, who already carry elevated liver risk throughout their reproductive years, the postmenopausal transition could represent a period of compounding vulnerability. Insulin resistance and body composition changes associated with menopause may amplify the metabolic disturbances that PCOS has been causing for decades. Women in this group arguably warrant closer liver surveillance as they age, though formal guidelines specific to postmenopausal women with a history of PCOS remain limited.